This page contains brief information about ivosidenib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
US Brand Name(s)
FDA label information for this drug is available at DailyMed.
Use in Cancer
Ivosidenib is approved to treat:
- Acute myeloid leukemia (AML) that has relapsed (come back) or is refractory (does not respond to treatment). It is used in adult patients whose AML has a certain mutation in the isocitrate dehydrogenase-1 (IDH1) gene.
Ivosidenib is also being studied in the treatment of other types of cancer.
More About Ivosidenib
Definition from the TCH Drug Dictionary – Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Targeted Drug Approved for Acute Myeloid Leukemia with IDH1 Gene Mutations
Targeted Cancer Therapies
Clinical Trials Accepting Patients
Find Clinical Trials for Ivosidenib – Check for trials from TCH’s list of cancer clinical trials now accepting patients.